Corvus Pharmaceuticals, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value
Corvus Pharmaceuticals, Inc. (CRVS) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value of $1.12 per share for the 12-month period ending 2023-12-31, per its 10-K filed 2024-03-19.
Discontinued › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Nonvested, Weighted Average Grant Date Fair Value
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue · last filed 2024-03-19
- Corvus Pharmaceuticals, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2023 was $1.12, a 62.32% increase from fiscal 2022.
- Corvus Pharmaceuticals, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2022 was $0.69, a 64.25% decline from fiscal 2021.
- Corvus Pharmaceuticals, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2021 was $1.93, a 27.44% decline from fiscal 2020.
- Corvus Pharmaceuticals, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2020 was $2.66, a 5.14% increase from fiscal 2019.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 11 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 12 month |
|---|---|---|
| 2023-12-31 | $1.12 10-K · filed 2024-03-19 | |
| 2022-12-31 | $0.69 10-K · filed 2024-03-19 | |
| 2021-12-31 | $1.93 10-K · filed 2024-03-19 | |
| 2020-12-31 | $2.66 10-K · filed 2023-03-28 | |
| 2019-12-31 | $2.53 10-K · filed 2022-03-10 | |
| 2018-12-31 | $5.23 10-K · filed 2021-03-25 | |
| 2017-12-31 | $8.93 10-K · filed 2020-03-09 | |
| 2016-12-31 | $10.78 10-K · filed 2019-03-07 | |
| 2015-12-31 | $4.37 10-K · filed 2018-03-01 | |
| 2014-12-31 | $0.22 10-K · filed 2017-03-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| Pacira BioSciences, Inc. (PCRX) | United States | $1.020B | 69.03 |
| Kura Oncology, Inc. (KURA) | United States | $0.967B | -3.29 |
| Arbutus Biopharma Corp (ABUS) | $0.965B | 6.19 | |
| MoonLake Immunotherapeutics (MLTX) | Switzerland | $1.031B | -5.43 |
| Savara Inc (SVRA) | United States | $1.044B | -9.10 |
| Jade Biosciences, Inc. (JBIO) | United States | $0.936B | -9.21 |
| MANNKIND CORP (MNKD) | United States | $1.058B | -30.41 |
| Alto Neuroscience, Inc. (ANRO) | United States | $1.065B | -11.02 |
| Apnimed, Inc. (APMD) | United States | $0.899B |